Dow Surges Over 100 Points; Pfizer Earnings Top Views
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 05 2025
0mins
Source: Benzinga
Market Performance: U.S. stocks rose this morning, with the Dow Jones gaining over 100 points, while Pfizer reported better-than-expected earnings and raised its FY 2025 EPS guidance.
Sector Movements: Consumer discretionary shares increased by 0.7%, but energy stocks fell by 0.4%. Notable stock movements included significant gains for SolarMax Technology and Y-mAbs Therapeutics, while Agilon Health saw a drastic decline of 57%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 27.370
Low
24.00
Averages
28.56
High
35.00
Current: 27.370
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LATITUDE Study Shows Long-Acting Injectable Treatment Significantly Reduces Virological Failure Risk
- Significant Findings: The final data from the LATITUDE phase III trial indicate that switching to the long-acting injectable treatment Cabenuva reduced the risk of virological failure by nearly half over 48 weeks, highlighting the potential advantages of this treatment approach in HIV management.
- Participant Demographics: The study enrolled 453 participants facing challenges with daily oral antiretroviral therapy (ART), with 63% being Black/African American, 29% female, and 17% Hispanic, demonstrating the broad applicability of this treatment option.
- Efficacy Comparison: Among the 152 participants receiving Cabenuva, 19% experienced treatment failure, compared to 36% in the 154 participants continuing oral ART, indicating a significant advantage of long-acting injectable treatment in maintaining viral suppression.
- Future Research Directions: ViiV Healthcare is conducting the CROWN study to evaluate the efficacy of Cabenuva in individuals who are not yet virally suppressed, further validating the treatment's potential across different patient populations.
See More
CDC Vaccine Advisory Committee Meeting Delayed to March
- Meeting Postponed: The CDC's Advisory Committee on Immunization Practices, originally scheduled for February 26, has been delayed to mid-March, with no finalized date, potentially impacting timely updates and implementation of vaccine policies.
- Legal Challenge: The postponement is linked to a lawsuit challenging recent changes made by HHS Secretary Robert F. Kennedy Jr. regarding committee member appointments, highlighting concerns over the transparency of CDC's decision-making, which may affect public trust in vaccinations.
- Medical Groups' Appeal: Several leading medical groups have urged a federal judge in Boston to bar the CDC from holding its next ACIP meeting, reflecting strong dissatisfaction with the committee member selection process, which could lead to increased resistance against CDC's vaccine policy formulation.
- Lack of CDC Response: The CDC and its parent agency, the U.S. Department of Health and Human Services, declined to comment on media inquiries, and this silence may further exacerbate public skepticism regarding its decision-making processes, impacting trust in the CDC.
See More
High-Yield Investment Opportunities: Pfizer and UPS
- Pfizer's Turnaround Potential: Pfizer currently offers a 6.2% dividend yield and has committed to maintaining this level, rapidly addressing a shortfall in the GLP-1 weight loss market through acquisitions and distribution partnerships, showcasing its strong capabilities in the pharmaceutical sector with future opportunities in oncology and migraines.
- UPS's Profitability Growth: UPS has a 5.5% dividend yield, and its stock price has recently risen due to early signs of a successful turnaround, with management focusing on high-margin businesses; despite a decline in U.S. volume, profitability per piece has improved, indicating successful strategic adjustments.
- Investor Confidence Rebound: As Pfizer and UPS improve their business operations, investor confidence in both companies is rising, particularly in a high-yield investment environment, making their dividends increasingly attractive and potentially highlighting them as future investment opportunities.
- Long-Term Outlook: UPS's guidance for 2026 suggests that its dividend is secure, and if the company can maintain current business trends, future earnings growth could make the dividend not only safe but also sustainable over the long term, appealing to investors seeking stable returns.
See More
Walmart's Guidance Falls Short of Expectations
- Guidance Miss: Walmart's latest earnings report projects adjusted EPS for the fiscal year between $2.75 and $2.85, falling short of Wall Street's $2.96 forecast, resulting in a premarket stock drop of over 2%.
- Challenges Under New CEO: With John Furner taking the helm amid intensifying market competition, investor focus on his strategic direction is increasing, which could impact stock performance.
- Market Performance Review: Despite a recent stock increase of over 21% and nearly 175% over the past five years, the lowered guidance may raise concerns about Walmart's future growth potential among investors.
- Industry Dynamics Impact: On the same day as Walmart's report, Wayfair posted its first annual sales gain, while Etsy's stock rose after beating earnings expectations, indicating a potential pressure on Walmart from the recovering retail sector.
See More
NIH Director to Serve as Acting CDC Director Amid Leadership Changes
- Leadership Changes: NIH Director Jay Bhattacharya is set to take on the role of acting CDC Director until President Trump appoints a permanent replacement, reflecting significant leadership shifts within the Trump administration's health department.
- Resignation of Predecessor: Former acting CDC Director Jim O’Neill resigned as part of a leadership shake-up, also stepping down from his role as Deputy Health Secretary, and is expected to be nominated by Trump to lead the National Science Foundation, indicating a focus on scientific leadership.
- Dismissal Due to Policy Misalignment: HHS Secretary Robert F. Kennedy Jr. fired former CDC Director Susan Monarez less than a month into her tenure, citing her failure to align with the Trump administration's healthcare policies, highlighting the administration's strict adherence to policy coherence.
- Industry Implications: Amid these changes, pharmaceutical companies like Pfizer and Johnson & Johnson are experiencing market volatility, with Pfizer's valuation still not recovering, illustrating the fragility of the industry in light of shifting governmental policies.
See More
Moderna's Flu Vaccine Receives FDA Review Approval
- FDA Review Decision: The FDA's agreement to review Moderna's experimental mRNA flu vaccine reverses its earlier refusal, stunning Wall Street and the medical community, marking a significant advancement in vaccine development.
- Positive Market Reaction: Following the FDA review announcement, Moderna's shares rose over 6%, reflecting investor confidence in the company's future flu vaccine market potential and paving the way for its goal of breaking even by 2028.
- New Application Strategy: Moderna's revised regulatory approach seeks full approval for adults aged 50 to 64 and accelerated approval for those 65 and older, addressing FDA criticisms of its trial design and enhancing the vaccine's market competitiveness.
- Changing Regulatory Environment: The FDA's decision highlights significant shifts in U.S. vaccine regulatory policies, particularly under the leadership of the new Secretary of Health and Human Services, with Moderna's application process facing stricter scrutiny, illustrating the complexities and challenges of vaccine regulation.
See More
LATITUDE Study Shows Long-Acting Injectable Treatment Significantly Reduces Virological Failure Risk
- Significant Findings: The final data from the LATITUDE phase III trial indicate that switching to the long-acting injectable treatment Cabenuva reduced the risk of virological failure by nearly half over 48 weeks, highlighting the potential advantages of this treatment approach in HIV management.
- Participant Demographics: The study enrolled 453 participants facing challenges with daily oral antiretroviral therapy (ART), with 63% being Black/African American, 29% female, and 17% Hispanic, demonstrating the broad applicability of this treatment option.
- Efficacy Comparison: Among the 152 participants receiving Cabenuva, 19% experienced treatment failure, compared to 36% in the 154 participants continuing oral ART, indicating a significant advantage of long-acting injectable treatment in maintaining viral suppression.
- Future Research Directions: ViiV Healthcare is conducting the CROWN study to evaluate the efficacy of Cabenuva in individuals who are not yet virally suppressed, further validating the treatment's potential across different patient populations.
See More
CDC Vaccine Advisory Committee Meeting Delayed to March
- Meeting Postponed: The CDC's Advisory Committee on Immunization Practices, originally scheduled for February 26, has been delayed to mid-March, with no finalized date, potentially impacting timely updates and implementation of vaccine policies.
- Legal Challenge: The postponement is linked to a lawsuit challenging recent changes made by HHS Secretary Robert F. Kennedy Jr. regarding committee member appointments, highlighting concerns over the transparency of CDC's decision-making, which may affect public trust in vaccinations.
- Medical Groups' Appeal: Several leading medical groups have urged a federal judge in Boston to bar the CDC from holding its next ACIP meeting, reflecting strong dissatisfaction with the committee member selection process, which could lead to increased resistance against CDC's vaccine policy formulation.
- Lack of CDC Response: The CDC and its parent agency, the U.S. Department of Health and Human Services, declined to comment on media inquiries, and this silence may further exacerbate public skepticism regarding its decision-making processes, impacting trust in the CDC.
See More
High-Yield Investment Opportunities: Pfizer and UPS
- Pfizer's Turnaround Potential: Pfizer currently offers a 6.2% dividend yield and has committed to maintaining this level, rapidly addressing a shortfall in the GLP-1 weight loss market through acquisitions and distribution partnerships, showcasing its strong capabilities in the pharmaceutical sector with future opportunities in oncology and migraines.
- UPS's Profitability Growth: UPS has a 5.5% dividend yield, and its stock price has recently risen due to early signs of a successful turnaround, with management focusing on high-margin businesses; despite a decline in U.S. volume, profitability per piece has improved, indicating successful strategic adjustments.
- Investor Confidence Rebound: As Pfizer and UPS improve their business operations, investor confidence in both companies is rising, particularly in a high-yield investment environment, making their dividends increasingly attractive and potentially highlighting them as future investment opportunities.
- Long-Term Outlook: UPS's guidance for 2026 suggests that its dividend is secure, and if the company can maintain current business trends, future earnings growth could make the dividend not only safe but also sustainable over the long term, appealing to investors seeking stable returns.
See More
Walmart's Guidance Falls Short of Expectations
- Guidance Miss: Walmart's latest earnings report projects adjusted EPS for the fiscal year between $2.75 and $2.85, falling short of Wall Street's $2.96 forecast, resulting in a premarket stock drop of over 2%.
- Challenges Under New CEO: With John Furner taking the helm amid intensifying market competition, investor focus on his strategic direction is increasing, which could impact stock performance.
- Market Performance Review: Despite a recent stock increase of over 21% and nearly 175% over the past five years, the lowered guidance may raise concerns about Walmart's future growth potential among investors.
- Industry Dynamics Impact: On the same day as Walmart's report, Wayfair posted its first annual sales gain, while Etsy's stock rose after beating earnings expectations, indicating a potential pressure on Walmart from the recovering retail sector.
See More
NIH Director to Serve as Acting CDC Director Amid Leadership Changes
- Leadership Changes: NIH Director Jay Bhattacharya is set to take on the role of acting CDC Director until President Trump appoints a permanent replacement, reflecting significant leadership shifts within the Trump administration's health department.
- Resignation of Predecessor: Former acting CDC Director Jim O’Neill resigned as part of a leadership shake-up, also stepping down from his role as Deputy Health Secretary, and is expected to be nominated by Trump to lead the National Science Foundation, indicating a focus on scientific leadership.
- Dismissal Due to Policy Misalignment: HHS Secretary Robert F. Kennedy Jr. fired former CDC Director Susan Monarez less than a month into her tenure, citing her failure to align with the Trump administration's healthcare policies, highlighting the administration's strict adherence to policy coherence.
- Industry Implications: Amid these changes, pharmaceutical companies like Pfizer and Johnson & Johnson are experiencing market volatility, with Pfizer's valuation still not recovering, illustrating the fragility of the industry in light of shifting governmental policies.
See More
Moderna's Flu Vaccine Receives FDA Review Approval
- FDA Review Decision: The FDA's agreement to review Moderna's experimental mRNA flu vaccine reverses its earlier refusal, stunning Wall Street and the medical community, marking a significant advancement in vaccine development.
- Positive Market Reaction: Following the FDA review announcement, Moderna's shares rose over 6%, reflecting investor confidence in the company's future flu vaccine market potential and paving the way for its goal of breaking even by 2028.
- New Application Strategy: Moderna's revised regulatory approach seeks full approval for adults aged 50 to 64 and accelerated approval for those 65 and older, addressing FDA criticisms of its trial design and enhancing the vaccine's market competitiveness.
- Changing Regulatory Environment: The FDA's decision highlights significant shifts in U.S. vaccine regulatory policies, particularly under the leadership of the new Secretary of Health and Human Services, with Moderna's application process facing stricter scrutiny, illustrating the complexities and challenges of vaccine regulation.
See More
